Compare Anheuser-Busch Inbev SA (BUD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs ResMed Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $79.31 (market cap $159.01B), while ResMed Inc. trades at $225.25 (market cap $32.61B). The key difference: Anheuser-Busch Inbev SA is far larger — about 4.9× ResMed Inc.'s market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| BUD | RMD | |
|---|---|---|
Market Cap | $159.01B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $293.73 |
52-Week Low | $57.93 | $182.82 |
Enterprise Value | $223.42B | $31.97B |
Dividend Yield | 1.67% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.
The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
